简介：　　角膜作为人眼屈光系统的重要组成部分,其地形、屈光力和厚度的准确测量直接决定着屈光手术的设计和角膜疾病的诊断.通常角膜地形图仪测量角膜前表面的地形,是角膜屈光力的主要来源,近年的研究表明角膜后表面的形状同样也影响着角膜的屈光力[1].角膜的厚度影响着内皮细胞层的屏障和泵功能,它的准确测量对于角膜疾病的诊断和避免屈光手术术后圆锥角膜的发生起着重要的作用[2].……

简介：目的：对比分析伴虹膜异色的青光眼睫状体炎综合征与Fuchs综合征患者的临床表现及特点,对两种疾病的鉴别要点作出分析及总结,利于临床医生对这两种疾病进行鉴别诊断。方法：对本院自2000年至今收治住院的3例伴虹膜异色的青光眼睫状体炎综合征（Posner-Schlossman’ssyndrome,PSS）患者进行详细的临床检查及研究,根据其临床资料总结出该病的临床特点,并对伴虹膜异色的PSS与Fuchs综合征的鉴别要点作出分析及总结。结果：共收集了3例伴虹膜异色的PSS患者,均为单眼反复发病,病程均在10a以上,发作时眼压明显升高,可达30.00～60.00mmHg,持续时间一般为3～7d,可自行缓解或用药后缓解,间歇期眼压正常,该3例患者除了具有典型的PSS表现外,虹膜均轻度异色。总结了该病在发作期及间歇期的临床表现,从发病情况、眼压波动情况、KP形态、晶状体情况、眼底及视功能情况详细论述了伴虹膜异色的青光眼睫状体炎综合征与Fuchs综合征的区别,并针对两种疾病的治疗提出了不同建议。结论：结合我们所提出的鉴别要点,对患者进行详细的临床检查,可以对这两种疾病进行鉴别诊断。

简介：目的评价带线羟基磷灰石义眼座(HA)无包裹植入的临床疗效.方法对29例眼球摘除术后患者,采用带线羟基磷灰石义眼座作为眼窝植入物,无包裹直接植入.Ⅰ期植入21例.Ⅱ期植入8例.结果分别随访5-18月,4眼术后出现球结膜裂开,2眼术后轻度上睑下垂,1眼术后五月义眼座中度暴露,均经相应治疗后恢复.其他病例手术效果良好,无植入物脱出及移位,义眼座活动度良好.结论带线羟基磷灰石义眼座直接植入术,具有操作简单、材料易得、并发症少等优点,具有良好的应用前景.

简介：目的采用不同色彩多焦视网膜电图（mfERG）刺激模式刺激正常眼黄斑部视网膜,观察不同刺激模式mfERG的波形改变及其特征,为将不同色彩刺激模式mfERG应用于黄斑疾病的检测提供正常基线标准和评估检查的可行性。方法分别采用黑/白刺激模式、黑/红刺激模式和黑/绿刺激模式对19例正常视力成年志愿者进行检测,比较分析一阶kernel反应（FOK）的平均反应密度和峰时变化特征,以及稳态闪烁光反应（flicker-30Hz）的平均反应密度和峰时的变化特征。结果正常人FOK以及flicker-30Hz1~5环P1波潜时与刺激色彩的亮度呈负相关,而P1波平均反应密度与刺激色彩亮度呈正相关,P1波峰时和平均反应密度与平均亮度均呈线性回归关系,表现为其亮度特征。结论不同色彩刺激模式存在亮度效应,由不同色彩的不同亮度特征性改变可以客观反映黄斑区不同亮度通道的功能情况。

简介：目的：观察增生型糖尿病视网膜病变（proliferativediabeticretinopathy,PDR）的多焦视网膜电图（multifocalelectroreti-nogram,mf-ERG）的图像特征及临床意义。方法：对临床确诊的PDR患者40例44眼（PDR组）和正常对照组40例40眼进行mf-ERG检查,并对所得数据进行统计分析。结果：PDR患者组mf-ERG1～5环的反应密度均低于正常对照组,且有显著性差异,N1波潜伏期在4环、P1波潜伏期在2～5环与正常对照组相比显著延长。结论：Mf-ERG可有效地评价PDR患者视网膜的功能。

简介：目的：通过对视网膜脱离患者术前、术后的血流动力学研究及视网膜功能的了解,判断视网膜脱离患者的术后恢复情况,并探讨两种检测方法的临床价值。方法：对我院62例孔源性视网膜脱离患者,通过彩色多普勒（CDI）检测视网膜中央动脉（CRA）的收缩期峰值流速（Vmax）、舒张末期流速（Vmin）、阻力指数（RI）;多焦视网膜电图（mfERG）分别对视网膜脱离患者的术前、术后进行检测,并以对侧正常眼作对照组。结果：CDI术前患眼与对照眼的CRA各项指标比较,差异无统计学意义。术后2wk视网膜脱离眼CRA的Vmax,Vmin均较术前降低,RI增高,差异有统计学意义（P〈0.05）。视网膜脱离术后患者脱离区mfERG的a波、b波振幅密度均明显高于术前,潜伏期比手术前明显缩短,有统计学意义（P〈0.05）。结论：通过mfERG,CDI的联合检测能及时了解视网膜脱离术后的视网膜复位情况及硅胶海绵垫压后CRA的血流情况,从而避免视网膜脱离术后视网膜部分复位不良,巩膜因缺血引起局部坏死等情况发生。

简介：目的：通过多焦视网膜电图（multifocalelectroretinography,mf-ERG）在中心性浆液性脉络膜视网膜病变（centralserouschorioretinopathy,CSC）治疗前后的观察,提高CSC诊断的准确性,并指导临床诊疗,评估预后。方法：设置有比较性的CSC观察组和双眼正常的对照组。观察组有31例CSC患者都是单眼发病,这些患者每只眼（包括患眼与对侧眼）在发病期与恢复期都经过眼科的系统检查,包括最佳矫正视力、眼底荧光血管造影、OCT和mf-ERG,并记录这些检查的数据。对照组有30例,与观察组年龄范围相同,同样做上述检查并记录数据。对两组数据进行对比分析。结果：在CSC发病期,mf-ERG显示患眼平均视网膜振幅密度在1环为60.54±18.20nV/degree2,比对照组（110.94±31.20nV/degree2）低45.43%（P〈0.01）,在2环为38.12±10.81nV/degree2,比对照组（60.91±11.43nV/degree2）低37.42%（P〈0.05）。在恢复期,mf-ERG显示患眼平均视网膜振幅密度在1环为93.71±14.13nV/degree2,比对照组（110.94±31.20nV/degree2）低15.53%（P〈0.05）;在2环为51.16±10.34nV/degree2,比对照组（60.91±11.43nV/degree2）低16.01%（P〈0.05）。另外,我们还发现,观察组31例患者中有8例对侧眼也显示出异常,平均视网膜振幅密度在1环为62.41nV/degree2,其余23例患者对侧眼未发现异常。结论：多焦视网膜电图有助于中心性浆液性脉络膜视网膜病变患者的临床治疗与随访观察,对中心性浆液性脉络膜视网膜病变患者的诊断、病情评估及预后都起着重要的作用。

简介：目的：对湖北地区20～29岁人群的角膜散光情况与不同近视度数的关系进行调查,找出其变化规律。方法：用角膜地形图对随机抽取的2254例湖北地区20～29岁青年居民进行散光度、轴向及近视度数的测定,并分析其变化规律。结果：湖北地区20～29岁居民中,各个近视度段散光在26°～150°范围内所占人数比例最大,各个近视度段均呈现顺规散光人数多于逆规散光。其中女性高度近视段约为75.3%,中度近视段约为82.7%,低度近视段约为87.2%;男性高度近视段约为74.6%,中度近视段约为83.0%,低度近视段约为82.3%。20～29岁男性高度近视段顺规散光人数比例高于其他两组;女性低度近视段顺规散光人数比例低于其他两组,差异有统计学意义。20～29岁人群中女性中度近视段顺规散光人数比例高于同近视度男性组,且女性总体组顺规散光人数比例高于男性总体组,差异有统计学意义。20～29岁男、女性高度近视组200°以内散光人数比例均低于中度近视组,差异有统计学意义。结论：湖北地区20～29岁居民中,各个近视度段散光在26°～150°范围内所占人数比例最大,且各个近视度段不论男女均呈现顺规散光人数多于逆规散光;男性高度近视段顺规散光人数比例高于其他两组,女性低度近视段顺规散光人数比例低于其他两组;女性中度近视段顺规散光人数比例高于同近视度男性组,且女性总体组顺规散光人数比例高于男性总体组;男、女性高度近视组200°以内散光人数比例均低于中度近视组。

简介：目的分析比较角膜地形图与散瞳检影两种方法所测得的散光及与近视度数的关系。方法采用角膜地形图对290只准备行LASIK手术的近视眼进行检查,同时采用散瞳检影法检查记录近视度数及散光并对两种方法所得数据进行比较分析。结果两种方法在散光轴向上无显著性差异(P＞0．5)；而在散光度数方面有非常显著差异(P＜0．01)。角膜地形图检查及检影法所测得的散光度数均与屈光度增高成正比。结论角膜地形图能快速而准确地提供角膜的屈光状态指标；全眼散光仍应以散瞳检影后患眼接受的度数和散光轴作为标准；散光度数均与屈光度增高成正比。

简介：AIM:Tocomparetheregularityandaccuracyoflaserinsitukeratomileusis(LASIK)flapscreatedbytheZiemerFEMTOLDV'Classic'(Ziemer'Classic')andZiemerFEMTOLDVCrystalLinefemtosecondlaser(ZiemerCrystalLine).METHODS:Fourier-domainopticalcoherencetomography(RTVueOCT)wasusedtomeasurethemorphologyof200LASIKflapsof100consecutivepatientscreatedwiththeZiemerClassic(100flaps)ortheZiemerCrystalLine(100flaps)atoneweekpostoperatively.Flapthicknesswasevaluatedat36specifiedmeasurementpointsoneachflap.Forallprocedureswithbothlasers,thenominalflapthicknesswas110μm.RESULTS:ThemeanflapthicknessoftheZiemerCrystalLinegroup(102.49±2.68μm)wasthinnerthanthatoftheZiemerClassicgroup(107.65±5.09μm)(P<0.01).Averagethicknessofallflapswasuniformwithin4μmatallmeasurementpoints.TheflapsintheZiemerCrystalLinegroupweremoreregularthanthoseintheZiemerClassicgroupwhenmeasuredfromthecentertotheperiphery.Themaximumdeviationfromthenominal110μmof36measurementswas8μmintheZiemerClassicgroup,whileintheZiemerCrystalLinegroupitwas9μm.Withinthe3600measurementsonthe100eyes,differencesgreaterthan20μmwereobserved0.14%intheZiemerClassicgroup,and0.04%intheZiemerCrystalLinegroup.CONCLUSION:TheflapscreatedwiththeZiemerFEMTOLDVCrystalLinefemtosecondlaseraremoreuniformandthinnerthanthosecreatedbytheZiemerFEMTOLDVClassicfemtosecondlaser.

简介：AIM:Toestablishanuntransfectedhumancornealstromal(HCS)celllineandcharacterizeitsbiocompatibilitytoacellularporcinecornealstroma(aPCS).·METHODS:PrimaryculturewasinitiatedwithapurepopulationofHCScellsinDMEM/F12media(pH7.2)containing20%fetalbovineserumandvariousnecessarygrowthfactors.Theestablishedcelllinewascharacterizedbygrowthproperty,chromosomeanalysis,tumorigenicityassay,expressionofmarkerproteinsandfunctionalproteins.Furthermore,thebiocompatibilityofHCScellswithaPCSwasexaminedthroughhistologicalandimmunocytochemistryanalysesandwithlight,electronmicroscopies.·RESULTS:HCScellsproliferatedtoconfluence2weekslaterinprimarycultureandhavebeensubculturedtopassage140sofar.AcontinuousuntransfectedHCScelllinewithapopulationdoublingtimeof41.44hoursatpassage80hasbeendetermined.Resultsofchromosomeanalysis,morphology,combinedwiththeresultsofexpressionofmarkerproteinandfunctionalproteinssuggestedthatthecellsretainedHCScellproperties.Furthermore,HCScellshavenotumorigenicity,andwithexcellentbiocompatibilitytoaPCS.·CONCLUSION:Anuntransfectedandnon-tumorigenicHCScelllinehasbeenestablished,andthecellsmaintainedpositiveexpressionofmarkerproteinsandfunctionalproteins.Thecellline,withexcellentbiocompatibilitytoaPCS,mightbeusedforinvitroreconstructionoftissue-engineeredHCS.

简介：AIM:Todemonstratethemorphologyandstructureofinvitroreconstructedtissue-engineeredhumancornealepithelium(TE-HCEP)withseedercellsfromanuntransfectedHCEPcellline.·METHODS:TheTE-HCEPswerereconstructedinvitrowithseedercellsfromanuntransfectedHCEPcellline,andscaffoldcarriersofdenudedamnioticmembrane(dAM)inair-liquidinterfaceculturefor3,5,7and9days,respectively.Thespecimenswereexaminedwithhematoxylin-eosin(HE)stainingofparaffin-section,immunocytochemicalstaining,scanningandtransmissionelectronmicroscopy.·RESULTS:DuringinvitroreconstructionofTE-HCEP,HCEPcellsformeda3-4,6-7and8-10layersofanHCEP-likestructureondAMsinair-liquidinterfaceculturefor3,5and7days,respectively.Butthecellsdeceasedto5-6layersandthestructureofstraifiedepitheliumbecamelooseatday9.Andthecellsmaintainedpositiveexpressionofmarkerproteins(keratin3andkeratin12),cell-junctionproteins(zonulaoccludens-1,E-cadherin,connexin43andintegrinβ1)andmembranetransportproteinofNa+-K+ATPase.TheHCEPcellsinTE-HCEPwererichinmicrovillionapicalsurfaceandestablishednumerouscell-cellandcell-dAMjunctionsatday5.·CONCLUSION:ThemorphologyandstructureofthereconstructedTE-HCEPweresimilartothoseofHCEPinvivo.TheHCEPcellsinthereconstructedTE-HCEPmaintainedthepropertiesofHCEPcells,includingabilitiesofformingintercellularandcell-extracellularmatrixjunctionsandabilitiesofperformingmembranetransportation.TheuntransfectedHCEPcellsanddAMscouldpromisinglybeusedinreconstructionHCEPequivalentforclinicalcornealepitheliumtransplantation.

简介：AIM:Topresenttheoutcomeofmodifiedgridlaserphotocoagulation(GLP)indiffusediabeticmacularedema(DDME)ineyeswithoutextrafovealand/orvitreofovealtraction.METHODS:InclusioncriteriafortheretrospectivestudywereDDMEeyesofpatientswithtypeⅡdiabetesmellitusthathad≥4monthsoffollow-upfollowingGLP.Onlyoneeyeperpatientwasanalyzed.Using3-Dspectral-domainopticalcoherencetomography(3-DSDOCT),eyesthathadeitherextrafovealorvitreofovealtraction,orhadbeenpreviouslytreatedbyanintravitrealmedication(s)wereexcluded.TreatedDDMEeyesweredividedinto4groups:A)'Classic'DDMEthatinvolvedthecentralmacula;B)edemadidnotinvolvethemacularcenter;C)eyesassociatedwithcentralepiretinalmembrane(ERM);D)DDMEthatwasassociatedwithmacularcapillarydropout≥2disc-diameter(DD).RESULTS:GLPoutcomein35DDMEeyesafter4-24(mean,13.1±6.9)monthswasasfollows:GroupA)18eyeswith'classic'DDME.Followingoneor2(mean,1.2)GLPtreatments,best-correctedvisualacuity(BCVA)improvedby1-2Snellenlinesin44.4%(8/18)ofeyes,andworsenedby1linein11.1%(2/18).Centralmacularthickness(CMT)improvedby7%-49%(mean,26.6%)in77.8%(14/18)ofeyes.CausesofCMTworsening(n=4)werecommonlyexplainable,predominantly(n=3)associatedwithemergenceofextrafovealtraction,5-9monthspost-GLP.GroupB)GLP(s)inDDMEthatdidnotinvolvethemacularcenter(n=6)resultedinimprovedBCVAby1-2linesin2eyes.However,thecentralmaculabecameinvolvedintheedemaprocessaftertheGLPin3(50%)eyes,associatedwithanemergenceofextrafovealtractioninoneoftheseeyes4monthsfollowingtheGLP.GroupC)GLPfailedinall5eyesassociatedwithcentralERM.GroupD)GLPwasofpartialbenefitin2of6treatedeyeswithmacularcapillarydropout≥2DD.CONCLUSION:EyeswithDDMEthatinvolvedthemacularcenterwerefoundtoachievefavourableoutcomesafterGLP(s)duringmid-termfollow-up,unlesscomplicatedpre-GLPorpost-GLPbyvltreoretinalinterfaceabnormalities,oftenextrafovealtra